ClinicalTrials.gg
CompletedNCT07253207Updated Nov 28, 2025

Efficacy and Safety Study of Levomilnacipran Hydrochloride Extended-Release Capsules in Major Depressive Disorder

A Phase 3 interventional study of Levomilnacipran Hydrochloride Extended-Release Capsules and Duloxetine Hydrochloride Enteric Capsules in Major Depressive Disorder (MDD), sponsored by Zhejiang Huahai Pharmaceutical Co., Ltd.. Completed at 28 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-28.

Sponsored by Zhejiang Huahai Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Oct 2024, registered Nov 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
392
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing levomilnacipran in Depressive Disorder, Major — none open to participants now, none under way, none of them phase 3. Levomilnacipran · Depressive Disorder, Major.

Enrollment
9th of 14
392 · median 472
Started
2024
the only one that year
Phase 3
10 of 14
none open now
Registered
14th of 14
by date
Lead sponsor
1 of 14
Zhejiang Huahai Pharmaceutical Co., Ltd.

Among the 14 studies testing levomilnacipran in Depressive Disorder, Major, this one is the 9th largest by enrollment, is the only one that started in 2024, is one of 10 in phase 3, and was the 14th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

None of the 14 studies testing levomilnacipran in Depressive Disorder, Major is open now. The open studies under Depressive Disorder, Major, anywhere →

Where they have run

About levomilnacipran

Levomilnacipran: first FDA approval 2013 (FETZIMA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing levomilnacipran in Depressive Disorder, Major as a file.
02

Study summary

The purpose of this study is using Duloxetine Hydrochloride Enteric Capsules as the positive control, to evaluate the efficacy and safety of Levomilnacipran Hydrochloride Extended-Release Capsules in patients with Major Depressive Disorder (MDD).

03

Conditions studied

  • Major Depressive Disorder (MDD)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Outpatient patients aged 18 to 65 years (inclusive of 18 but exclusive of 65), regardless of gender;
  2. Meet the diagnostic criteria for depression as per the , Fifth Edition (DSM-5), with a duration of at least 3 months for first-episode cases (30 days per month);
  3. Current depressive episode confirmed using the Mini-International Neuropsychiatric Interview (M.I.N.I.) version 7.0.0 or higher;
  4. Total HAMD17 score ≥18 at screening and baseline visits;
  5. CGI-S score ≥4 at screening and baseline visits;
  6. Agree to use effective during the trial and for 30 days after the last dose (women of must have a negative pregnancy test before dosing and not be breastfeeding), and men and women must have no plans to donate sperm or eggs, respectively;
  7. Voluntarily participate in the trial and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Meet diagnostic criteria for other mental disorders (including but not limited to schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, obsessive-compulsive and related disorders, somatic symptom and related disorders);
  2. Previous failure to respond to adequate dose and duration (maximum recommended dose for MDD as per label for at least 4 weeks) of serotonin and norepinephrine reuptake inhibitors (including but not limited to milnacipran, levomilnacipran, duloxetine, venlafaxine, desvenlafaxine), or failure to respond to adequate dose and duration of at least two antidepressant drugs;
  3. Allergic to milnacipran, levomilnacipran, duloxetine, or of the trial drug, or have an allergic constitution;
  4. History of suicide attempt within 1 year prior to screening; suicidal or self-harming behavior during screening; HAMD17 item 3 (suicide) score ≥3; currently at high suicide risk;
  5. Depression secondary to other diseases;
  6. History of epileptic seizures (except for febrile convulsions in childhood);
  7. Received systematic electroconvulsive therapy, transcranial magnetic stimulation, transcranial direct current stimulation, systematic psychotherapy, or other treatments with antidepressant effects within 3 months prior to screening; received electroconvulsive therapy within 1 month prior to screening;
  8. Discontinuation of psychotropic drugs or their active metabolites less than 5 half-lives, or monoamine oxidase inhibitors less than 2 weeks, before randomization;
  9. Required to use drugs with interactions with the trial drug during the trial (including but not limited to monoamine oxidase inhibitors, other serotonergic drugs, drugs affecting coagulation, strong /CYP1A2/CYP2D6 inhibitors or inducers, alcohol, linezolid, and intravenous methylene blue);
  10. Conditions affecting drug swallowing or absorption, as judged by the investigator;
  11. Risk factors for angle-closure glaucoma, as judged by the investigator;
  12. Abnormal and clinically significant results from physical examinations or laboratory tests at screening or baseline, as judged by the investigator, including but not limited to , AST, total , or serum creatinine >1.5 times the , or thyroid-stimulating hormone outside the normal range;
  13. Current or past medical history of diseases or dysfunctions affecting the trial, as judged by the investigator, including but not limited to chronic or acute diseases of the nervous, motor, circulatory, respiratory, digestive, urinary, endocrine, reproductive, or immune systems;
  14. Clinically significant cardiovascular diseases, as judged by the investigator, including but not limited to atrial fibrillation, second- or third-degree atrioventricular block, myocardial infarction within 12 months, or heart function class III or above;
  15. interval ≥450 ms (males) or ≥470 ms (females), or other factors increasing the risk of QTcF prolongation or arrhythmic events (including but not limited to heart failure, hypokalemia, family history of long QT syndrome), or ECG heart rate \<50 bpm or >120 bpm (Note: QTcF = QT/(RR\^0.33));
  16. Resting seated systolic blood pressure \<90 mmHg or >140 mmHg, or diastolic blood pressure \<50 mmHg or >90 mmHg;
  17. Diagnosed with end-stage renal disease at screening or previously, as judged by the investigator;
  18. History of malignant tumors, as judged by the investigator at screening or previously;
  19. Positive virological screening for surface antigen (HBsAg), antibody (HCVAb), syphilis antibody, or (HIV) antibody during screening;
  20. History of drug or alcohol abuse;
  21. Weekly alcohol consumption exceeding 14 units in the 6 months prior to screening (1 unit = 360 mL beer, 45 mL 40% liquor, or 150 mL wine);
  22. Inability to comply with medication instructions, as judged by the investigator;
  23. Physiological or psychological conditions that may increase trial risks, affect protocol compliance, or prevent trial completion, as judged by the investigator;
  24. Participation in any clinical trial (received drugs or medical devices) within 30 days before signing the form;
  25. Concomitant diseases that may interfere with trial procedures or assessments, or other conditions deemed unsuitable for trial participation by the investigator.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
392 participants (actual)

Study arms

  • Active comparator
    Duloxetine Hydrochloride Enteric Capsules

    Drug: Duloxetine Hydrochloride Enteric Capsules

  • Experimental
    Levomilnacipran Hydrochloride Extended-Release Capsules

    Drug: Levomilnacipran Hydrochloride Extended-Release Capsules

Interventions

  • Treatment period: 1. Levomilnacipran Hydrochloride Extended-Release Capsules 20mg/day is to be given orally, once daily, for 1-2 days in the first week of treatment. 2. Levomilnacipran Hydrochloride Extended-Release Capsules 40mg/day is to be given orally, once daily, for 3-7 days in the first week of treatment. 3. Levomilnacipran Hydrochloride Extended-Release Capsules 80mg/day is to be given orally, once daily, for the second week of treatment. 4. Levomilnacipran Hydrochloride Extended-Release Capsules 40, 80 or 120mg/day (the dosage based on the participant's clinical response and tolerance) is to be given orally, once daily, for the weeks 3 to 8 of treatment. Reduction period: Dosage of 20-80mg/day based on the tolerable dose during the 8th week of treatment.

  • DrugDuloxetine Hydrochloride Enteric Capsules

    Treatment period: Duloxetine Hydrochloride Enteric Capsules 60mg/day is to be given orally, once daily, for 8 weeks. Reduction period: Duloxetine Hydrochloride Enteric Capsules 60mg/day is to be given orally, once daily, for 2 weeks.

06

What researchers measure

Primary outcomes

  1. The change from baseline in the total score of the 17-item Hamilton Depression Rating Scale (HAM-D17) after 8 weeks of treatment.

    Change from baseline at Week 8 in total score of the 17-item Hamilton Depression Rating Scale (HAM-D17) (Score range: 0-52; a higher score indicates greater severity of depressive symptoms.)

    Time frame: 8 weeks of treatment

07

Study locations

28 sites
  • Hefei Fourth People's Hospital
    Hefei, Anhui 230031, China
  • Wuhu Hospital of Beijing Anding Hospital, Capital Medical University
    Wuhu, Anhui 241003, China
  • Beijing Anding Hospital Capital Medical University
    Beijing, Beijing Municipality 100000, China
  • Beijing HuiLongGuan Hospital
    Beijing, Beijing Municipality 102200, China
  • Chongqing Mental Health Center
    Chongqing, Chongqing Municipality 401147, China
  • Affiliated Brain Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510370, China
  • Hebei Provincial Mental Health Center
    Baoding, Hebei 071030, China
  • The First Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
  • Hunan Provincial Second People's Hospital
    Changsha, Hunan 410007, China
  • Nantong Mental Health Center
    Nantong, Jiangsu 226005, China
  • Suzhou Guangji Hospital
    Suzhou, Jiangsu 215131, China
  • Wuxi Mental Health Center
    Wuxi, Jiangsu 214000, China
  • Zhenjiang Mental Health Center
    Zhenjiang, Jiangsu 212021, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
  • Jiangxi Provincial Psychiatric Hospital
    Nanchang, Jiangxi 330029, China
  • Jilin Provincial Neuropsychiatric Hospital
    Siping, Jilin 136000, China
  • The First Affiliated Hospital of Xi 'an Jiaotong University
    Xi'an, Shaanxi 710061, China
  • Xi 'an Mental Health Center
    Xi'an, Shaanxi 710199, China
  • Shandong Provincial Mental Health Center
    Jinan, Shandong 250014, China
  • Shanghai Pudong New Area Mental Health Center
    Shanghai, Shanghai Municipality 200124, China
  • Linfen Central Hospital
    Linfen, Shanxi 041099, China
  • The First Hospital of Shanxi Medical University
    Taiyuan, Shanxi 030001, China
  • Chengdu Fourth People's Hospital
    Chengdu, Sichuan 610041, China
  • Tianjin Fourth Central Hospital
    Tianjin, Tianjin Municipality 300074, China
  • The First Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650032, China
  • Hangzhou Seventh People's Hospital
    Hangzhou, Zhejiang 310007, China
  • Huzhou Third People's Hospital
    Huzhou, Zhejiang 313000, China
  • Ningbo University Affiliated Kangning Hospital
    Ningbo, Zhejiang 315201, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Jun 2025, 7 months.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 7 months is below that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Nov 28, 2025
StartActual
Oct 17, 2024
Primary completionActual
Jun 13, 2025
CompletionActual
Jul 22, 2025
Last update
Nov 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07253207
Lead sponsor
Zhejiang Huahai Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Nov 28, 2025
Start date
Oct 17, 2024
Primary completion
Jun 13, 2025
Completion
Jul 22, 2025
Last update
Nov 28, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levomilnacipran

Start the discussion